Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia.¶
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., et al. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine, 344(14), 1031-1037.
Cited by¶
2 citations across 2 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Intervention-Coupled Harm
- The mechanism-switch move replaces the entire mechanism with one whose coupled-harm signature differs — targeted therapy replacing cytotoxic chemotherapy, capability-based security replacing perimeter security — and is the only move that breaks the ratio.
This sourceDemonstrates targeted therapy (imatinib) exploiting a tumour-specific molecular marker rather than division rate, shifting the coupled-harm signature away from marrow toxicity.
Supported in partVerified against the work's full text
Druker et al. exemplify a targeted drug with minimal adverse effects versus interferon, but do not address capability-based security or that mechanism-switch is the only move that breaks the ratio.
“STI571 causes arrest of growth or apoptosis in hematopoietic cells that express BCR-ABL but does not affect normal cells.”
- The mechanism-switch move replaces the entire mechanism with one whose coupled-harm signature differs — targeted therapy replacing cytotoxic chemotherapy, capability-based security replacing perimeter security — and is the only move that breaks the ratio.
Domain-specific¶
- Translational Research
- Druker and colleagues' phase I dose-escalation trial tested safety, tolerability, and antileukemic activity, reporting substantial activity and supporting the molecular target's relevance in humans.
This sourcePrimary phase I evidence for translating a molecular target into human treatment. DOI: 10.1056/NEJM200104053441401.
- Druker and colleagues' phase I dose-escalation trial tested safety, tolerability, and antileukemic activity, reporting substantial activity and supporting the molecular target's relevance in humans.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 2 citations: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:21568cec6455 · see in the full table